$BIAFJun 16, 2026, 12:06 PMAI processed
bioAffinity (BIAF) to host July 21 webinar with Philips and 4DMedical on veteran lung screening
AI Summary
BioAffinity (BIAF/BIAFW) will host a July 21 NAVREF webinar with Philips and 4DMedical to highlight mobile CT screening, noninvasive CyPath® Lung testing and advanced functional imaging aimed at improving access and early detection of lung disease in U.S. veterans. CyPath Lung is marketed as a CLIA Laboratory Developed Test and the company cites a published study in high‐risk patients with small nodules (<20 mm) showing ~92% sensitivity and 99% negative predictive value, but the announcement contains no new clinical data or regulatory milestones.
Positives
- Webinar brings NAVREF, Philips and 4DMedical together to target VA clinicians and could raise awareness within veteran health networks
- CyPath Lung is commercially available today as a CLIA‑regulated Laboratory Developed Test (LDT)
- Company cites published trial metrics (≈92% sensitivity, 99% NPV) for CyPath in high‑risk patients with small nodules
Negatives
- Announcement is an educational webinar — no new clinical data, outcomes, or regulatory approvals were disclosed
- CyPath is marketed as an LDT and is not presented as an FDA‑cleared standalone diagnostic
- Cited performance is from a selected high‑risk cohort with small nodules, so broader generalizability is uncertain